Manufacturers report positive results from pivotal Phase 3 LOGICS Study for use of levoketoconazole for endogenous Cushing’s Syndrome

At the end of the randomised-withdrawal phase of this study, 54.5% more patients who were withdrawn to placebo had a loss of mean urinary free cortisol response as compared with those who remained on treatment (95.5% vs 40.9% respectively; p=0.0002).

Biospace Inc.